Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10158585 | 0.83 | ERN1 (0.62) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| 2,4,6-Trimethoxybenzaldehyde SCHEMBL34873 | 0.81 | ERN1 (0.74) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| 2,4,6-Trimethoxybenzaldehyde SCHEMBL28687257 | 0.79 | ERN1 (0.71) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| SCHEMBL348538 | 0.78 | LMNA (0.56) | ERN1LMNAALDH1A1ABCG2APLNR | |
| SCHEMBL21710556 | 0.78 | ERN1 (0.51) | ERN1LMNAPTGS2TDP1 | |
| 2,4,6-Trimethoxybenzaldehyde SCHEMBL28687256 | 0.77 | ERN1 (0.75) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| SCHEMBL1428091 | 0.77 | ERN1 (0.62) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| SCHEMBL1645590 | 0.77 | ERN1 (0.62) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| SCHEMBL28301424 | 0.75 | ABCB1 (0.50) | ERN1LMNAALDH1A1ABCG2CYP1A2 | |
| SCHEMBL30230047 | 0.74 | ERN1 (0.65) | ERN1LMNAALDH1A1ABCG2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288650-B2 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7074793-B2 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060128780-A1 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1315732-B1 | RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6841567-B1 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040186157-A1 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2004-09-23 | — | — | US | disclosed |
| EP-1315732-A2 | RADICICOL AND MONOCILLIN AND THEIR ANALOGUES AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20020091151-A1 | Novel macrocycles and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-07-11 | — | — | US | disclosed |
| WO-2002016369-A2 | NOVEL MACROCYCLES AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-1165562-A1 | CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | Cephalon, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000047583-A9 | CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000047583-A1 | CYCLIC SUBSTITUTED FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186157-A1 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | PIN1, PAICS, QPCT | ERN1 4285/4885LMNA 3578/4885ALDH1A1 1908/4885 |
| US-20020091151-A1 | Novel macrocycles and uses thereof | ABCE1, DCK, BDKRB1 | ERN1 1901/4885LMNA 1716/4885ALDH1A1 1572/4885 |
| US-20060128780-A1 | Cyclic substituted fused pyrrolocarbazoles and isoindolones | PIN1, PAICS, QPCT | ERN1 4285/4885LMNA 3578/4885ALDH1A1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.